Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
OCLS's Cash to Debt is ranked higher than
95% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. OCLS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
OCLS' s Cash to Debt Range Over the Past 10 Years
Min: 0.31  Med: 6.13 Max: No Debt
Current: No Debt
Equity to Asset 0.75
OCLS's Equity to Asset is ranked higher than
70% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. OCLS: 0.75 )
Ranked among companies with meaningful Equity to Asset only.
OCLS' s Equity to Asset Range Over the Past 10 Years
Min: -0.21  Med: 0.47 Max: 0.8
Current: 0.75
-0.21
0.8
Interest Coverage No Debt
OCLS's Interest Coverage is ranked higher than
87% of the 470 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 123.58 vs. OCLS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
OCLS' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: No Debt
F-Score: 3
Z-Score: -11.54
M-Score: -2.52
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -57.58
OCLS's Operating margin (%) is ranked lower than
88% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.82 vs. OCLS: -57.58 )
Ranked among companies with meaningful Operating margin (%) only.
OCLS' s Operating margin (%) Range Over the Past 10 Years
Min: -806.93  Med: -92.90 Max: -21.84
Current: -57.58
-806.93
-21.84
Net-margin (%) -56.35
OCLS's Net-margin (%) is ranked lower than
88% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.45 vs. OCLS: -56.35 )
Ranked among companies with meaningful Net-margin (%) only.
OCLS' s Net-margin (%) Range Over the Past 10 Years
Min: -893.92  Med: -96.64 Max: 27.33
Current: -56.35
-893.92
27.33
ROE (%) -86.01
OCLS's ROE (%) is ranked lower than
93% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. OCLS: -86.01 )
Ranked among companies with meaningful ROE (%) only.
OCLS' s ROE (%) Range Over the Past 10 Years
Min: -1759.66  Med: -181.65 Max: 46.27
Current: -86.01
-1759.66
46.27
ROA (%) -65.55
OCLS's ROA (%) is ranked lower than
94% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. OCLS: -65.55 )
Ranked among companies with meaningful ROA (%) only.
OCLS' s ROA (%) Range Over the Past 10 Years
Min: -235.36  Med: -86.51 Max: 22.39
Current: -65.55
-235.36
22.39
ROC (Joel Greenblatt) (%) -384.27
OCLS's ROC (Joel Greenblatt) (%) is ranked lower than
87% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.76 vs. OCLS: -384.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OCLS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1069.56  Med: -685.47 Max: 541.28
Current: -384.27
-1069.56
541.28
Revenue Growth (3Y)(%) -24.00
OCLS's Revenue Growth (3Y)(%) is ranked lower than
91% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. OCLS: -24.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OCLS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -27.3  Med: -4.60 Max: 53.6
Current: -24
-27.3
53.6
EBITDA Growth (3Y)(%) -19.10
OCLS's EBITDA Growth (3Y)(%) is ranked lower than
81% of the 531 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. OCLS: -19.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OCLS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -34.70 Max: 372
Current: -19.1
0
372
EPS Growth (3Y)(%) -23.20
OCLS's EPS Growth (3Y)(%) is ranked lower than
80% of the 487 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. OCLS: -23.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OCLS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -54.1  Med: -25.45 Max: 357.7
Current: -23.2
-54.1
357.7
» OCLS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with OCLS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.63
OCLS's P/B is ranked higher than
66% of the 706 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. OCLS: 1.63 )
Ranked among companies with meaningful P/B only.
OCLS' s P/B Range Over the Past 10 Years
Min: 0.88  Med: 7.47 Max: 264.25
Current: 1.63
0.88
264.25
P/S 0.79
OCLS's P/S is ranked higher than
82% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.72 vs. OCLS: 0.79 )
Ranked among companies with meaningful P/S only.
OCLS' s P/S Range Over the Past 10 Years
Min: 0.49  Med: 3.18 Max: 18.2
Current: 0.79
0.49
18.2
Current Ratio 4.93
OCLS's Current Ratio is ranked higher than
79% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. OCLS: 4.93 )
Ranked among companies with meaningful Current Ratio only.
OCLS' s Current Ratio Range Over the Past 10 Years
Min: 0.54  Med: 1.88 Max: 4.93
Current: 4.93
0.54
4.93
Quick Ratio 4.28
OCLS's Quick Ratio is ranked higher than
80% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. OCLS: 4.28 )
Ranked among companies with meaningful Quick Ratio only.
OCLS' s Quick Ratio Range Over the Past 10 Years
Min: 0.5  Med: 1.71 Max: 4.32
Current: 4.28
0.5
4.32
Days Inventory 67.97
OCLS's Days Inventory is ranked higher than
78% of the 643 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 118.46 vs. OCLS: 67.97 )
Ranked among companies with meaningful Days Inventory only.
OCLS' s Days Inventory Range Over the Past 10 Years
Min: 35.89  Med: 56.47 Max: 76.35
Current: 67.97
35.89
76.35
Days Sales Outstanding 64.40
OCLS's Days Sales Outstanding is ranked higher than
59% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.01 vs. OCLS: 64.40 )
Ranked among companies with meaningful Days Sales Outstanding only.
OCLS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.97  Med: 66.36 Max: 151.99
Current: 64.4
39.97
151.99
Days Payable 66.32
OCLS's Days Payable is ranked lower than
55% of the 558 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.59 vs. OCLS: 66.32 )
Ranked among companies with meaningful Days Payable only.
OCLS' s Days Payable Range Over the Past 10 Years
Min: 50.97  Med: 88.32 Max: 394.99
Current: 66.32
50.97
394.99

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.61
OCLS's Price/Net Cash is ranked higher than
75% of the 201 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.02 vs. OCLS: 3.61 )
Ranked among companies with meaningful Price/Net Cash only.
OCLS' s Price/Net Cash Range Over the Past 10 Years
Min: 3.76  Med: 14.57 Max: 68.25
Current: 3.61
3.76
68.25
Price/Net Current Asset Value 1.87
OCLS's Price/Net Current Asset Value is ranked higher than
89% of the 465 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. OCLS: 1.87 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OCLS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.91  Med: 10.41 Max: 250.25
Current: 1.87
1.91
250.25
Price/Tangible Book 2.00
OCLS's Price/Tangible Book is ranked higher than
72% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.51 vs. OCLS: 2.00 )
Ranked among companies with meaningful Price/Tangible Book only.
OCLS' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.05  Med: 7.32 Max: 183.75
Current: 2
1.05
183.75
Price/Median PS Value 0.30
OCLS's Price/Median PS Value is ranked higher than
95% of the 612 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.18 vs. OCLS: 0.30 )
Ranked among companies with meaningful Price/Median PS Value only.
OCLS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.18  Med: 1.20 Max: 5.3
Current: 0.3
0.18
5.3
Earnings Yield (Greenblatt) (%) -160.11
OCLS's Earnings Yield (Greenblatt) (%) is ranked lower than
97% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. OCLS: -160.11 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OCLS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 6.4  Med: 27.85 Max: 71.9
Current: -160.11
6.4
71.9

More Statistics

Revenue(Mil) $16
EPS $ -0.56
Beta0.74
Short Percentage of Float5.11%
52-Week Range $0.65 - 1.97
Shares Outstanding(Mil)16.42

Analyst Estimate

Mar16 Mar17 Mar18 Mar19
Revenue(Mil) 15 16 19 23
EPS($) -0.44 -0.36 -0.20 0.10
EPS without NRI($) -0.44 -0.36 -0.20 0.10

Latest Earnings Webcast

Call starts at Feb 04, 2016 04:30 PM EST

» More Conference Calls

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:O8Z1.Germany,
Oculus Innovative Sciences Inc was incorporated under the laws of the State of California in April 1999 as Micromed Laboratories, Inc. In August 2001, it changed its name to Oculus Innovative Sciences, Inc. In December 2006, it reincorporated under the laws of the State of Delaware. The Company develops, manufactures and markets a family of tissue care products that cure infections and, through a separate mechanism of action, enhance healing while reducing the need for antibiotics. Infection is a serious potential complication in both chronic and acute wounds, and controlling infection is a critical step in wound healing. The Company's platform technology, called Microcyn(r), is a proprietary solution of electrically charged oxychlorine small molecules designed to treat a wide range of organisms that cause disease (pathogens). These include viruses, fungi, spores and antibiotic-resistant strains of bacteria, such as methicillin-resistant Staphylococcus aureus, or MRSA, and vancomycin-resistant Enterococcus, or VRE, in wounds, as well as Clostridium difficile (C. diff), a highly contagious bacteria spread by human contact. The Company's products compete with a variety of products used for wound cleaning, debriding and moistening, including sterile saline, and chlorhexadine-based products, and they also compete with a large number of prescription and over-the-counter products for the prevention and treatment of infections, including topical anti-infectives, such as Betadine, silver sulfadiazine, hydrogen peroxide, Dakin's solution and hypochlorous acid, and topical antibiotics, such as Neosporine, Mupirocin and Bacitracin. Government authorities in the United States at the federal, state and local levels and foreign countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, promotion, advertising, distribution, sampling, marketing, and import and export of pharmaceutical products, biologics and medical devices.
» More Articles for NAS:OCLS

Headlines

Articles On GuruFocus.com
Experience a Unique Realm Of Science Fiction With Sony’s Virtual Reality Headset Mar 12 2015 
Focus on New Technologies Can Drive Facebook's Growth Jan 22 2015 
Oculus Innovative Sciences Inc. Reports Operating Results (10-Q) Feb 04 2011 
Oculus Innovative Sciences Inc. Reports Operating Results (10-Q) Nov 04 2010 
Oculus Innovative Sciences Inc. (OCLS) COO James J Schutz buys 18,500 Shares Aug 09 2010 
Oculus Innovative Sciences Inc. (OCLS) COO James J Schutz buys 18,500 Shares Aug 09 2010 
Oculus Innovative Sciences Inc. Reports Operating Results (10-Q) Aug 05 2010 
Oculus Innovative Sciences Inc. Reports Operating Results (10-Q) Feb 11 2010 
Oculus Innovative Sciences Inc. (OCLS) COO James J Schutz buys 20,000 Shares Dec 09 2009 
Weekly CFO Buys Highlight: Information Services Group Inc., BioFuel Energy Corp., Oculus Innovative Nov 22 2009 

More From Other Websites
Oculus Innovative Sciences to Present at the Source Capital Group's 2016 Disruptive Growth &... Feb 05 2016
Oculus Innovative Sciences Inc Earnings Call scheduled for 4:30 pm ET today Feb 04 2016
OCULUS INNOVATIVE SCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 04 2016
Oculus Innovative Sciences Reports Third Quarter Financial Results Feb 04 2016
Q3 2016 Oculus Innovative Sciences Inc Earnings Release - After Market Close Feb 04 2016
Oculus Innovative Sciences Announces Fiscal Third Quarter 2016 Financial Results and Conference Call Jan 21 2016
Oculus Innovative Sciences Announces Fiscal Third Quarter 2016 Financial Results and Conference Call Jan 21 2016
A Turnaround Story Wall Street Hasn't Caught Onto Yet Jan 20 2016
40 under 40: Meet the financial wizards and local economic development leaders (Video) Jan 14 2016
Oculus Innovative Sciences Receives European CE Mark for New MucoClyns™ for First Responders Jan 14 2016
Oculus Innovative Sciences Receives European CE Mark for New MucoClyns™ for First Responders Jan 14 2016
40 under 40: Find out which real estate and legal leaders made the cut (Video) Jan 13 2016
Announcing 40 Under 40's tech titans in the class of 2016 (Video) Jan 12 2016
Edited Transcript of OCLS earnings conference call or presentation 5-Nov-15 9:30pm GMT Jan 08 2016
12 Biotechs With Binary Events Coming This Year Jan 08 2016
8 things you need to know this morning Jan 08 2016
Innovation Sparks Advancement of New Treatments for Atopic Dermatitis Jan 07 2016
The Zacks Analyst Blog Highlights: Streamline Health Solutions, WaferGen Bio-systems, HealthEquity,... Dec 22 2015
Santa Brings FDA and Health Canada Approvals for New Dermatology Products Dec 21 2015
5 Growth Stocks to Buy on High Obamacare Enrollment Dec 21 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK